Hyrimoz HCF (adalimumab biosimilar) high-concentration formulation is launched in Europe, aiming to improve patient care
Sandoz, announces the launch of Hyrimoz (adalimumab) citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe
The medicine will become available to patients progressively across European markets, starting today.
Hyrimoz HCF, like the currently available 50mg/mL version of Hyrimoz, is indicated for all conditions covered by the reference medicine: rheumatic diseases, Crohn's disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa.
Rebecca Guntern, President Europe Sandoz said: “People living with chronic inflammatory conditions can experience debilitating effects on daily life. The launch of Hyrimoz HCF in Europe is a key milestone in offering an additional treatment option to those that need it and showcases our unwavering commitment to expanding access to high-quality medicines.”
Hyrimoz citrate-free HCF is an updated formulation (100 mg/mL) to the currently available Hyrimoz 50 mg/mL and offers a 50 percent reduction in injection volume, thereby potentially decreasing the number of injections required for patients who need 80 mg/mL or higher dosing. The HCF formulation is administered with the familiar Hyrimoz SensoReady pen, aiming for an enhanced yet familiar patient experience.
Related news and insights
UCB announced that the European Commission (EC) has granted a marketing authorization for Zilbrysq (zilucoplan) as an add-on to standard therapy for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive
The FDA has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies. Reports were received from clinical trials and/or postmarketing adverse event (AE) data sources.
Pfizer Inc. announced topline data from the Phase II clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.